Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma Journal Article

Authors: Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Jacob, A. G.; Matasar, M. J.; McArthur, G. N.; McCall, S. J.; Moskowitz, A. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Vander Els, N.; Verwys, S. L.; Yang, J.; Younes, A.; Zelenetz, A. D.; Zhang, Z.; Moskowitz, C. H.
Article Title: Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
Abstract: This multicenter pilot study assessed the safety and efficacy of brentuximab vedotin (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved site radiation therapy (ISRT). Patients with newly diagnosed, early stage classical Hodgkin lymphoma (HL) with unfavorable-risk features were treated with 4 cycles of BV and AVD. Patients who achieved a negative positron emission tomography (PET) scan (Deauville score of 1-3) received 30 Gy ISRT. Thirty patients received treatment and were assessable for toxicity. Twenty-nine patients completed 4 cycles of BV + AVD, and 25 patients BV + AVD + 30 Gy ISRT. No clinically significant noninfectious pneumonitis was observed. Serious adverse events(≥grade 3) were reported in 4 patients, including febrile neutropenia, peripheral neuropathy, and hypertension. After 2 and 4 cycles of BV + AVD, 90%(26 of 29) and 93%(27 or 29) of patients achieved a negative PET scan, respectively. Two patients with biopsy-proven primary refractory HL were treated off-study. All 25 patients who completed BV + AVD + ISRT achieved a complete response. With a median follow-up of 18.8 months, by intent to treat, the 1-year progression-free survival is 93.3% (95% confidence interval, 84-102). Overall, the treatment was well-tolerated with no evidence of significant pulmonary toxicity. The majority of patients (≥90%) achieved negative interim PET scans after 2 and 4 cycles of BV + AVD. Excludingthe 2 primary refractory patients, all patients are disease free, suggesting that this is a highly active treatment program even in patients with substantial disease bulk. © 2016 by The American Society of Hematology.
Journal Title: Blood
Volume: 128
Issue: 11
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2016-09-15
Start Page: 1458
End Page: 1464
Language: English
DOI: 10.1182/blood-2016-03-703470
PROVIDER: scopus
PUBMED: 27458003
PMCID: PMC5025897
Notes: Article -- Export Date: 3 October 2016 -- Source: Scopus
Citation Impact
MSK Authors
  1. Zhigang Zhang
    310 Zhang
  2. Joachim Yahalom
    488 Yahalom
  3. Carol Portlock
    201 Portlock
  4. Craig Moskowitz
    397 Moskowitz
  5. Ariela Noy
    269 Noy
  6. Maria Lia Palomba
    219 Palomba
  7. Steven M Horwitz
    465 Horwitz
  8. Heiko Schoder
    362 Schoder
  9. Andrew D Zelenetz
    639 Zelenetz
  10. Alison Moskowitz
    212 Moskowitz
  11. Paul Hamlin
    212 Hamlin
  12. Matthew J Matasar
    180 Matasar
  13. Philip C Caron
    50 Caron
  14. David J Straus
    286 Straus
  15. Susan J McCall
    15 McCall
  16. Anita Kumar
    87 Kumar
  17. April Chiu
    57 Chiu
  18. Alexandra G Jacob
    7 Jacob
  19. Joanna C Yang
    37 Yang
  20. Anas Younes
    286 Younes
  21. Stephanie Lisl Verwys
    4 Verwys